Pluri Inc.

PLUR Healthcare Biotechnology

Pluri Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.0 million, down 24.0% from fiscal 2025. In the quarter to June 2026, revenue fell 15.8%, EPS grew 48.0%, free cash flow grew 25.0% and total debt rose 3.43%, each against the same quarter a year earlier.

0.93 0.01 −1.06%
Market cap
$11.9M
P/E
0.0×
Fwd P/E
−0.8×
Dividend yield
—
F-score
1/9
Altman Z
−30.41
Beneish M
−4.29
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 3 3 1
ROE
789.88% 430.96% 408.10% 260.35%
ROA
(65.26%) (85.06%) (80.48%) (74.95%)
ROIC
(227.46%) (252.28%) (306.99%) (526.92%)
Return on Tangible Assets
167.35% 155.40% 128.53% 106.23%
Average Days of Receivables
80.93 46.07 33.49 31.25
Free Cash Flow per Share
(2.35) (2.38) (2.16) (2.07)
Free Cash Flow
(21.10) (22.01) (21.69) (20.20)
Other line items

Show all line items

Columns are period end dates